MedTrace Logo

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects

NCT06062680 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-10-02

No results posted yet for this study

Summary

This study used a single-center, randomized, open-label, three-period, crossover trial design. Fifteen healthy subjects were planned to be enrolled, and the subjects were randomly assigned to any group A, B and C in the order of screening, with 5 cases in each group

Conditions

  • Adult Patients With Chronic Primary ITP
  • Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy

Interventions

DRUG

Herombopag Olamine Tablets

Three Herombopag Olamine Tablets is administered to healthy subjects.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2023-11-15
Completion
2023-11-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06062680 on ClinicalTrials.gov